Literature DB >> 30834547

Reply to 'Comment on 'Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised controlled VaSera trial' by Faconti et al.'

Luca Faconti1,2,3, J Kennedy Cruickshank2,3, Andrew James Webb1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30834547      PMCID： PMC6475683          DOI： 10.1111/bcp.13890

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Myocardial wall stress: from hypertension to heart tension.

Authors:  Phil Chowienczyk; Ajay Shah
Journal:  Hypertension       Date:  2012-06-04       Impact factor: 10.190

2.  Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes.

Authors:  Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2016-11       Impact factor: 4.335

3.  Comment on 'Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised controlled VaSera trial' by Faconti et al.

Authors:  Danielle Aparecida Guimaraes; Jose Eduardo Tanus-Santos
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

4.  Reply to 'Comment on 'Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised controlled VaSera trial' by Faconti et al.'

Authors:  Luca Faconti; J Kennedy Cruickshank; Andrew James Webb
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335

5.  Reducing Arterial Stiffness Independently of Blood Pressure: The VaSera Trial.

Authors:  Charlotte E Mills; Virginia Govoni; Luca Faconti; Maria-Linda Casagrande; Steven V Morant; Andrew J Webb; J Kennedy Cruickshank
Journal:  J Am Coll Cardiol       Date:  2017-09-26       Impact factor: 24.094

6.  Inorganic Nitrite Selectively Dilates Epicardial Coronary Arteries.

Authors:  Kevin O'Gallagher; Faisal Khan; Sami A Omar; Sundeep Kalra; Edward Danson; Ana R Cabaco; Katherine Martin; Narbeh Melikian; Ajay M Shah; Andrew J Webb
Journal:  J Am Coll Cardiol       Date:  2018-01-23       Impact factor: 24.094

7.  Nitrite exerts antioxidant effects, inhibits the mTOR pathway and reverses hypertension-induced cardiac hypertrophy.

Authors:  Danielle A Guimaraes; Madla A Dos Passos; Elen Rizzi; Lucas C Pinheiro; Jefferson H Amaral; Raquel F Gerlach; Michele M Castro; Jose E Tanus-Santos
Journal:  Free Radic Biol Med       Date:  2018-03-09       Impact factor: 7.376

8.  It is rocket science - why dietary nitrate is hard to 'beet'! Part II: further mechanisms and therapeutic potential of the nitrate-nitrite-NO pathway.

Authors:  Charlotte Elizabeth Mills; Jibran Khatri; Perry Maskell; Chimed Odongerel; Andrew James Webb
Journal:  Br J Clin Pharmacol       Date:  2016-05-06       Impact factor: 4.335

Review 9.  It is rocket science - why dietary nitrate is hard to 'beet'! Part I: twists and turns in the realization of the nitrate-nitrite-NO pathway.

Authors:  Jibran Khatri; Charlotte Elizabeth Mills; Perry Maskell; Chimed Odongerel; Andrew James Webb
Journal:  Br J Clin Pharmacol       Date:  2016-05-06       Impact factor: 4.335

10.  Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures.

Authors:  Sami A Omar; Henry Fok; Katharina D Tilgner; Ashok Nair; Joanne Hunt; Benyu Jiang; Paul Taylor; Phil Chowienczyk; Andrew J Webb
Journal:  Circulation       Date:  2014-12-22       Impact factor: 29.690
View more
  1 in total

1.  Reply to 'Comment on 'Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised controlled VaSera trial' by Faconti et al.'

Authors:  Luca Faconti; J Kennedy Cruickshank; Andrew James Webb
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.